Beyond the Bottleneck: Engineering Sensitive Bespoke MRD Assays

Tumor-informed liquid biopsy stands as the gold standard for monitoring minimal residual disease (MRD), but scientists face significant hurdles in assay development and adoption. Operational complexity, workflow bottlenecks, and the need to deliver highly personalized, rapid, and sensitive testing at scale continue to impede progress.

In this live roundtable webinar, brought to you by Twist Bioscience, leading experts will discuss the technical and operational challenges that limit MRD testing and assay development, while highlighting emerging approaches to address them.